Clinuvel Pharmaceuticals Limited American Depositary Shares

CLINUVEL PHARMACEUTICALS LTD announced a strategic reorganisation that includes relocating its corporate headquarters to the United States and reducing its global workforce by approximately 10 to 20 percent, effective 1 January 2027. The restructuring aims to refocus operations exclusively on the U.S. pharmaceutical market, which represents over 40 percent of the global pharmaceutical market by value, and to unlock deeper capital pools. Chief Operating Officer Lachlan Hay said the move responds to U.S. investor preference for U.S.-focused companies and positions the firm to capture the sizable U.S. vitiligo market, estimated at approximately six million patients. Over 66 percent of CLINUVEL's shareholder register is already held by foreign investors, with the majority of new shareholders from North America and Europe. The company is listed on the Australian Securities Exchange and the Nasdaq Stock Market.